Search
for
Sort by
Research 181–210 of 350
- Endocrinology
- Recent advances in neuropeptide-related omics and gene editing: Spotlight on NPY and somatostatin and their roles in growth and food intake of fish
- Insulin resistance as risk factor for the development of type 2 diabetes mellitus: a systematic approach
- A Complex Clinical Situation in Polycystic Ovary Syndrome: HAIR‐AN Syndrome ‘‘Case Report’’
- Design and fabrication of customizable microneedles enabled by 3D printing for biomedical applications
- Safety of testosterone treatment in postmenopausal women
- Forsythiaside A protects against focal cerebral ischemic injury by mediating the activation of the Nrf2 and endoplasmic reticulum stress pathways
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
- Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome
- Androgenetic alopecia
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Cold atmospheric microwave plasma (CAMP) stimulates dermal papilla cell proliferation by inducing β-catenin signaling
- Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
- Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study
- Glucagon-Like Peptide-1 Receptor Agonists and Hair Loss: Current Evidence and Potential Mechanisms
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
- Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
- Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
- Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
- Association Between Androgenetic Alopecia and Glucagon‐Like Peptide‐1 Receptor Treatment in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study
- A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
- GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review